In a closely watched test of the Digital Millennium Copyright Act, the U.S. Court of Appeals for the Federal Circuit has upheld a lower court’s ruling that a garage-door opener designed as a replacement for a model made by a rival manufacturer does not violate the DMCA.
Auto parts supplier ArvinMeritor, Inc. has sued rival Eaton Corp. for infringement over a transmission patent.
Chipmaker Genesis Microchip has penned licensing deals with Samsung Electronics and Tovis Co. in the wake of its victory at the U.S. International Trade Commission (ITC) in a dispute over a patent for liquid crystal display (LCD) controllers.
In a major victory for India’s burgeoning software industry, the country’s government is planning to allow software patents under limited conditions as part of a major overhaul of the country’s patent system.
India is considering the creation of a special court for intellectual property cases, according to a government official.
In a move designed to curb patent evergreening, India’s government is considering legislation that would limit data exclusivity to four years, according to local media reports.
Taiwanese chip makers MStar Semiconductor, Media Reality Technologies (MRT) and Trumpion Microelectronics infringed a patent for liquid crystal display (LCD) controllers held by rival Genesis Microchip, the U.S. International Trade Commission said in a final determination.
Taiwan Semiconductor has filed an unfair import complaint with the U.S. International Trade Commission (ITC), seeking a probe of a mainland rival already targeted in a trade-secret lawsuit in California.
Disk-drive maker Cornice has fired a legal volley back at one of the companies that sued it for patent infringement earlier this year, filing a countersuit against rival Seagate Technology over its patent rights for tiny disk drives.
U.K. drug maker GlaxoSmithKline has abandoned its claim to a Chinese patent for a component of its popular diabetes drug Avandia, but is holding on to two other patents on the drug in an escalating battle with Chinese generic makers.
India’s government has decided to broaden the scope for invoking compulsory licensing as part of an overhaul of the country’s patent law, according to local media reports.
India’s government will introduce a bill “in the next two weeks” to overhaul its patent system and introduce pharmaceutical product patents, a minister has told local media.
Weil, Gotshal & Manges LLP has hired Alexander J. Hadjis from Fish & Richardson and charged him with building a new patent litigation practice in Washington, D.C.
The U.S. International Trade Commission has launched an investigation into whether Sony Corp.'s digital cameras and cellular phones with digital image capabilities are infringing a patent held by California-based Ampex Corp., the ITC said Wednesday.
A coalition of 17 Chinese drug makers have set up a joint-stock company to produce an erectile dysfunction drug in the wake of Pfizer’s loss of patent protection for Viagra in China, according to the Beijing Morning Post.
The U.S. International Trade Commission will investigate a complaint by Gateway Inc. that Hewlett-Packard Co. is violating U.S. trade laws by importing computers and parts infringe its patents.
The U.S. International Trade Commission has ruled for Fuji Photo Film Co. in a patent infringement complaint against a New Jersey company that rebuilds used Fujitsu disposable cameras and sells them without brand names at a discount.
Taiwanese chipmakers VIA Technologies and MediaTek have settled their far-flung litigation over patents, copyrights and trade secrets related to chipsets and firmware for optical storage devices, fought in Taiwanese and U.S. courts since 2002.
A number of Chinese drug makers are preparing to use the government’s rejection of a patent for Pfizer’s Viagra as a precedent for a challenge to GlaxoSmithKline’s diabetes drug Avandia, the Financial Times reports.
In a move designed to offset a broadside of litigation when India adopts product patents in 2005, India’s generics industry has offered to pay 4% of their turnover as royalty to drugs’ originators.